UBS lowered the firm’s price target on Gentex (GNTX) to $25 from $26 and keeps a Neutral rating on the shares. Gentex reported “good” Q4 results and the 2026 outlook was in line with estimates, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNTX: